Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) Director Kristine Ball sold 18,000 shares of the firm’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $104.93, for a total value of $1,888,740.00. Following the sale, the director directly owned 18,000 shares of the company’s stock, valued at $1,888,740. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oruka Therapeutics Stock Up 0.3%
ORKA traded up $0.36 during trading on Friday, hitting $105.35. The company’s stock had a trading volume of 679,678 shares, compared to its average volume of 1,033,539. The firm’s 50 day moving average price is $89.68 and its two-hundred day moving average price is $72.36. Oruka Therapeutics, Inc. has a 12 month low of $25.23 and a 12 month high of $115.51. The stock has a market capitalization of $7.14 billion, a price-to-earnings ratio of -49.93 and a beta of -0.34.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). On average, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -2.52 earnings per share for the current year.
Institutional Investors Weigh In On Oruka Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its stake in shares of Oruka Therapeutics by 4.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,991 shares of the company’s stock worth $333,000 after buying an additional 168 shares during the last quarter. Algert Global LLC lifted its holdings in Oruka Therapeutics by 3.5% in the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after buying an additional 180 shares during the period. AlphaCentric Advisors LLC lifted its holdings in Oruka Therapeutics by 3.4% in the third quarter. AlphaCentric Advisors LLC now owns 6,752 shares of the company’s stock valued at $562,000 after buying an additional 221 shares during the period. GAMMA Investing LLC lifted its holdings in Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after buying an additional 250 shares during the period. Finally, Nykredit A S bought a new position in Oruka Therapeutics in the second quarter valued at approximately $29,000. 56.44% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on ORKA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Piper Sandler reissued an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, BTIG Research reiterated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, November 10th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $141.80.
Get Our Latest Stock Analysis on Oruka Therapeutics
More Oruka Therapeutics News
Investors following ORKA have been watching these news items:
- Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
- Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
- Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing
Oruka Therapeutics Company Profile
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Featured Articles
- Five stocks we like better than Oruka Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
